Wissenschaftlerin mit Pipette in einem hellen biomedizinischen Labor

Projekt

Methyltransferase inhibitors for treatment of COVID19

Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.

Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.

Themengebiete

Hochschulen

Förderungen